Erythropoietin protects sensory axons against paclitaxel-induced distal degeneration

Melli, Giorgia; Jack, Christelene; Lambrinos, George L.; Ringkamp, Mathias; Höke, Ahmet

doi:10.1016/j.nbd.2006.08.014

Cited by 73 publications

(78 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

Section: Chemotherapy-induced Peripheral Neuropathymentioning

confidence: 99%

“…These models predominantly used morphological assessments, including epidermal nerve fiber density [97] as the primary outcome measures. These models have been successfully used to evaluate potential therapeutic compounds [79,97,98]. An important concept that emerged from a unique study of paclitaxel CIPN in mice has been the dependency of the phenotype on the genetic background of the mice [99].…”

Section: Chemotherapy-induced Peripheral Neuropathymentioning

confidence: 99%

See 1 more Smart Citation

Animal Models of Peripheral Neuropathies

Höke

2012

Neurotherapeutics

Self Cite

View full text Add to dashboard Cite

Peripheral neuropathies are common neurological diseases, and various animal models have been developed to study disease pathogenesis and test potential therapeutic drugs. Three commonly studied disease models with huge public health impact are diabetic peripheral neuropathy, chemotherapy-induced peripheral neuropathy, and human immunodeficiency virus-associated sensory neuropathies. A common theme in these animal models is the comprehensive use of pathological, electrophysiological, and behavioral outcome measures that mimic the human disease.

show abstract

Section: Chemotherapy-induced Peripheral Neuropathymentioning

confidence: 99%

Section: Chemotherapy-induced Peripheral Neuropathymentioning

confidence: 99%

Animal Models of Peripheral Neuropathies

Höke

2012

Neurotherapeutics

Self Cite

View full text Add to dashboard Cite

show abstract

“…12,111,116,[138][139][140] However, lower doses of chemotherapeutics, which cause an enhanced sensitivity to nociceptive stimuli, cause a degeneration or loss of IENF, similar to that observed in patients. 115,116,[141][142][143] One advantage of using animal models is that studies can be designed to determine whether this IENF loss is a cause or an effect of changes in neuronal sensitivity following chemotherapy treatment, although, to date, these studies have not been performed. The data from the animal models suggest that both increases and decreases in neuronal sensitivity occur following treatment with chemotherapeutics, depending on the endpoint measured and the dosing paradigm administered.…”

Section: Experimental Studies: Animal Models Of Cipnmentioning

confidence: 99%

Chemotherapy-Induced Peripheral Neuropathy

Fehrenbacher

2015

Progress in Molecular Biology and Translational Science

View full text Add to dashboard Cite

“…Thus, prevention of axonal degeneration must be a major goal for therapeutic approaches to peripheral neuropathies. EPO has been shown to prevent apoptosis of DRG (dorsal root ganglia) sensory neurons [31] and axonal degeneration in various models of peripheral neuropathies [31,32,[57][58][59]. These preclinical observations raise the possibility of use of rhEPO in peripheral neuropathies but the recent concern for vascular side effects hampered clinical trials.…”

Section: Epo In Models Of Peripheral Neuropathymentioning

confidence: 99%